406 filings
Page 7 of 21
CORRESP
ta5v0 ow59r1a4jrqt0
24 Oct 22
Correspondence with SEC
12:00am
425
hholfl8
17 Oct 22
Business combination disclosure
4:03pm
8-K
3n16iv
17 Oct 22
Clinical trial anticipated to begin in late 2022
4:02pm
UPLOAD
p080dquwj7es
14 Oct 22
Letter from SEC
12:00am
425
f7ydpa 50kvngma8y
13 Oct 22
Business combination disclosure
4:03pm
8-K
ny3ppjghajjmom2p5nj
13 Oct 22
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy
4:01pm
425
sildvqy6e6gb3axk0n34
11 Oct 22
Business combination disclosure
8:02am
8-K
i3ao3c af64epgujg
11 Oct 22
Kineta Announces Participation in Upcoming October 2022 Investor Conferences
8:00am
425
8jxcl0mdhbul
4 Oct 22
Business combination disclosure
4:04pm
8-K
8tin7s6ojc0m
4 Oct 22
Kineta Appoints Keith Baker as Chief Financial Officer
4:01pm
CORRESP
gfflh
3 Oct 22
Correspondence with SEC
12:00am
SEC STAFF LETTER
9lbuqr4qatb0s zz
26 Sep 22
SEC staff letter
12:00am
UPLOAD
qr4i1j 9t4pj
26 Sep 22
Letter from SEC
12:00am
425
wfa9lnz 4otq
23 Sep 22
Business combination disclosure
8:01am
8-K
gbj 5lqole
23 Sep 22
Regulation FD Disclosure
8:00am
425
zr8lmdgr9p1y68hn9yk
14 Sep 22
Business combination disclosure
4:04pm
8-K
8w4rbgl
14 Sep 22
Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium
4:01pm
425
ra63r87pdmb9hh3awlk6
12 Sep 22
Business combination disclosure
4:01pm
8-K
8w9 zdwbtn
12 Sep 22
Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference
4:00pm